Detail
| LncRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 Sequence |
| Ensembl | ENSG00000130600 |
| RefSeq | NR_002196 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, etc. |
| Sample | breast cancer cell line, breast cancer tumor tissues. |
| Expression Pattern | down-regulation |
| Function Description | Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.H19 is associated with drug-resistance in breast cancer cells.Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was -0.1. Several miRNAs and lncRNAs, including let-7a and H19, provide prognostic information for many cancers. |
| Pubmed ID | 29963109 |
| Year | 2018 |
| Title | Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients. |
| External Links |
| Links for H19 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.